The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice
Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucle...
Saved in:
Published in | Psychopharmacologia Vol. 167; no. 3; pp. 257 - 264 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Berlin
Springer
01.05.2003
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 0033-3158 1432-2072 |
DOI | 10.1007/s00213-003-1432-z |
Cover
Abstract | Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine.
The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice.
Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 microg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair.
MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 microg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice.
These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission. |
---|---|
AbstractList | Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine.RATIONALENicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine.The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice.OBJECTIVESThe present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice.Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 microg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair.METHODSRats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 microg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair.MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 microg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice.RESULTSMPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 microg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice.These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission.CONCLUSIONSThese results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission. Rationale. Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine. Objectives. The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice. Methods. Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 μg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair. Results. MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 μg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice. Conclusions. These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission. Rationale. Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine.Objectives. The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA /2J mice.Methods. Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 mu g per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair.Results. MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 mu g per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice.Conclusions. These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission. Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine. The present study investigated the effects of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) on intravenous nicotine self-administration in Wistar rats and DBA/2J mice. Rats were allowed to self-administer nicotine (0.01, 0.03 mg/kg per infusion) or respond for food on one of two fixed-ratio 5 schedules of reinforcement. Drug-naive mice were acutely exposed, in pairs, to nicotine (0, 0.016, 0.048, 0.16, 0.48 microg per infusion) self-administration under a fixed ratio 1 schedule of reinforcement, with one subject controlling the delivery of nicotine to both subjects in each pair. MPEP (1-9 mg/kg) dose-dependently reduced nicotine self-administration with no effect on food-maintained responding in the rats. Self-administration of nicotine was obtained only at the 0.048 microg per infusion dose by the mice, and administration of MPEP (5-20 mg/kg) decreased nicotine self-administration response rates in the mice. These results indicate that blockade of mGluR5 decreased nicotine self-administration in both rats and mice, and are consistent with findings showing a role of mGluR5 in cocaine self-administration. It is postulated that mGluR5 plays an essential role in mediating the reinforcing effects of nicotine, possibly but not exclusively, via modulation of mesolimbic dopaminergic neurotransmission. |
Author | Markou, Athina Semenova, Svetlana Paterson, Neil E. Gasparini, Fabrizio |
Author_xml | – sequence: 1 givenname: Neil E. surname: Paterson fullname: Paterson, Neil E. – sequence: 2 givenname: Svetlana surname: Semenova fullname: Semenova, Svetlana – sequence: 3 givenname: Fabrizio surname: Gasparini fullname: Gasparini, Fabrizio – sequence: 4 givenname: Athina surname: Markou fullname: Markou, Athina |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14862478$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/12682710$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUtLxDAUhYMoOj5-gBsJgu6qebVJlyK-QHEYdB1icquRNtWkXeivN-OMCoKYLHIh37nce84mWg19AIR2KTmihMjjRAijvCCEF1RwVryvoMlnwYhkq2iSP3jBaak20GZKzyQfocQ62qCsUkxSMkGzuyfA3UU7zkpswmAe--DTgG-mZ1PswEYwCRwO3vaDD4ATtE1hXOfnVDSD7wP2AecqZbnDnbewjdYa0ybYWb5b6P787O70sri-vbg6PbkuLFflUEglmKgFAWYqWjOXZ25cU3HJObWUg3M1r21Vy3ytNRZc-eCsbVRTy0ooxbfQ4aLvS-xfR0iD7nyy0LYmQD8mLTmTlaLkX5AqWbLMZXD_F_jcjzHkJTSjqi6loFWG9pbQ-NCB0y_Rdya-6S9PM3CwBEyypm2iCdanH06oigk5n18uOBv7lCI02vrh09LsrG81JXqesl6krHOYeh6ufs9K-kv53fxPzQdtPadB |
CODEN | PSYPAG |
CitedBy_id | crossref_primary_10_1038_tp_2016_132 crossref_primary_10_1016_j_biopsych_2020_06_020 crossref_primary_10_1016_j_ejphar_2010_01_029 crossref_primary_10_1007_s00213_010_2095_1 crossref_primary_10_1016_j_bcp_2013_07_007 crossref_primary_10_1016_j_neuropharm_2005_06_007 crossref_primary_10_1016_j_bmcl_2006_04_032 crossref_primary_10_1016_j_pbb_2014_09_020 crossref_primary_10_1016_j_bbr_2012_01_042 crossref_primary_10_1002_wmts_18 crossref_primary_10_1021_jm070078r crossref_primary_10_1016_j_bmcl_2011_04_047 crossref_primary_10_1097_01_ALC_0000093601_33119_E3 crossref_primary_10_1016_j_neulet_2008_12_028 crossref_primary_10_1016_j_neuropharm_2011_08_028 crossref_primary_10_1016_j_drugalcdep_2008_09_006 crossref_primary_10_1038_nrn2515 crossref_primary_10_1038_aps_2014_93 crossref_primary_10_1039_c0ob01190h crossref_primary_10_1021_jm050570f crossref_primary_10_1007_s00213_015_4056_1 crossref_primary_10_1111_j_1749_6632_2011_06415_x crossref_primary_10_1016_j_brainresbull_2015_11_010 crossref_primary_10_1007_s00213_004_2069_2 crossref_primary_10_1016_j_conb_2013_02_013 crossref_primary_10_1038_aps_2009_46 crossref_primary_10_1016_j_biopsych_2020_02_017 crossref_primary_10_1007_s00213_010_1950_4 crossref_primary_10_1016_j_tips_2003_11_003 crossref_primary_10_1517_13543776_18_2_123 crossref_primary_10_1007_s00213_011_2189_4 crossref_primary_10_1097_WNR_0b013e3283021cc0 crossref_primary_10_1586_ecp_09_6 crossref_primary_10_1196_annals_1441_015 crossref_primary_10_1093_cercor_bhi087 crossref_primary_10_1016_j_bmcl_2007_03_066 crossref_primary_10_1016_j_ejphar_2007_06_003 crossref_primary_10_1016_j_drugalcdep_2011_11_002 crossref_primary_10_1016_j_tips_2004_03_009 crossref_primary_10_1111_j_1369_1600_2010_00235_x crossref_primary_10_1111_j_1460_9568_2005_03945_x crossref_primary_10_1007_s00213_010_1868_x crossref_primary_10_1016_j_pbb_2010_12_023 crossref_primary_10_1016_j_pharmthera_2013_12_012 crossref_primary_10_1016_j_biopsych_2010_01_005 crossref_primary_10_1016_j_lfs_2011_09_014 crossref_primary_10_1007_s00213_005_0163_8 crossref_primary_10_1016_j_ejphar_2004_07_056 crossref_primary_10_1016_j_neuropharm_2006_10_003 crossref_primary_10_1016_j_pharmthera_2009_11_002 crossref_primary_10_1038_npp_2008_140 crossref_primary_10_1093_alcalc_agh200 crossref_primary_10_1007_s00213_022_06266_7 crossref_primary_10_1016_j_tips_2005_04_005 crossref_primary_10_1017_S1461145707007845 crossref_primary_10_1016_j_alcohol_2007_11_001 crossref_primary_10_1017_S1461145709991064 crossref_primary_10_1111_j_1471_4159_2004_02920_x crossref_primary_10_1007_s00213_016_4220_2 crossref_primary_10_1124_jpet_103_052027 crossref_primary_10_1016_j_neuropharm_2009_10_001 crossref_primary_10_1038_sj_npp_1300845 crossref_primary_10_1016_j_bcp_2011_06_026 crossref_primary_10_1016_j_brainres_2007_10_007 crossref_primary_10_1016_j_biopsych_2009_09_016 crossref_primary_10_1093_ijnp_pyac034 crossref_primary_10_1016_j_neubiorev_2005_04_016 crossref_primary_10_1097_FBP_0b013e32832c7083 crossref_primary_10_1007_s00213_009_1479_6 crossref_primary_10_1016_j_neuropharm_2013_05_042 crossref_primary_10_1016_j_pbb_2011_03_015 crossref_primary_10_1007_s00213_005_0217_y crossref_primary_10_3390_toxics8040095 crossref_primary_10_1016_j_bmcl_2006_12_083 crossref_primary_10_1016_j_neubiorev_2015_07_010 crossref_primary_10_1177_0269881110367460 crossref_primary_10_1007_s00259_015_3301_5 crossref_primary_10_1016_j_neuropharm_2011_05_012 crossref_primary_10_1146_annurev_neuro_061010_113734 crossref_primary_10_1196_annals_1316_061 crossref_primary_10_1124_jpet_109_151357 crossref_primary_10_1016_j_ejphar_2007_01_046 crossref_primary_10_1007_s00213_007_0755_6 crossref_primary_10_1016_j_bbr_2010_12_024 crossref_primary_10_1097_FBP_0b013e3282f18d58 crossref_primary_10_1196_annals_1300_040 crossref_primary_10_1080_17460441_2018_1458090 crossref_primary_10_1016_j_bcp_2007_07_031 crossref_primary_10_1016_j_ddstr_2006_10_018 crossref_primary_10_1016_j_ejphar_2008_06_081 crossref_primary_10_1038_npp_2011_103 crossref_primary_10_1124_jpet_104_076406 crossref_primary_10_1016_j_biopsych_2006_03_053 crossref_primary_10_1007_s00213_015_4179_4 crossref_primary_10_1021_acschemneuro_8b00601 crossref_primary_10_1134_S0022093020060010 crossref_primary_10_1016_j_drugalcdep_2013_08_024 crossref_primary_10_1017_S1461145708009450 crossref_primary_10_1007_s00213_008_1069_z crossref_primary_10_1016_j_biopsych_2015_02_027 crossref_primary_10_1017_S1092852920001704 crossref_primary_10_1016_j_neuropharm_2006_05_005 crossref_primary_10_1038_npp_2008_50 crossref_primary_10_1016_j_bcp_2007_07_021 crossref_primary_10_1016_j_ejphar_2006_10_011 crossref_primary_10_1073_pnas_1210984110 crossref_primary_10_1111_j_1471_4159_2007_04818_x crossref_primary_10_1177_24705470231154842 crossref_primary_10_1124_jpet_105_090449 crossref_primary_10_1007_s00213_005_0155_8 crossref_primary_10_1007_s00213_004_2067_4 crossref_primary_10_3389_fnins_2015_00404 crossref_primary_10_1016_j_biopsych_2018_03_001 crossref_primary_10_1038_sj_npp_1300381 crossref_primary_10_1196_annals_1432_034 crossref_primary_10_1007_BF03033479 crossref_primary_10_1038_sj_npp_1301477 crossref_primary_10_1016_j_euroneuro_2008_05_004 crossref_primary_10_1016_j_bcp_2007_05_020 crossref_primary_10_1038_sj_npp_1300417 crossref_primary_10_1007_s00213_016_4487_3 crossref_primary_10_1016_j_neuropharm_2004_07_025 crossref_primary_10_2165_00023210_200822090_00001 crossref_primary_10_1016_j_neuropharm_2006_07_023 crossref_primary_10_3349_ymj_2008_49_2_175 crossref_primary_10_1124_mol_104_003319 crossref_primary_10_1007_s00213_004_2070_9 crossref_primary_10_1017_S1461145708008584 crossref_primary_10_1016_j_brainresbull_2012_01_010 crossref_primary_10_1016_j_devbrainres_2003_09_010 crossref_primary_10_1371_journal_pone_0024049 crossref_primary_10_1016_j_neubiorev_2015_06_004 crossref_primary_10_1111_j_1530_0277_2007_00570_x crossref_primary_10_1007_s00213_011_2578_8 crossref_primary_10_1007_s00213_006_0583_0 crossref_primary_10_1038_sj_npp_1301623 crossref_primary_10_1016_j_drugalcdep_2006_04_003 crossref_primary_10_1016_j_biopsych_2018_02_009 crossref_primary_10_1016_j_pharmthera_2007_04_007 crossref_primary_10_1016_j_neuropharm_2012_08_006 crossref_primary_10_1016_j_neuropharm_2023_109694 crossref_primary_10_1016_j_ejphar_2008_12_042 crossref_primary_10_1111_j_1369_1600_2010_00246_x crossref_primary_10_4103_0019_5545_33253 crossref_primary_10_1177_02698811241292902 crossref_primary_10_1176_foc_5_2_foc208 crossref_primary_10_1016_S1359_6446_03_02890_3 crossref_primary_10_1098_rstb_2008_0095 crossref_primary_10_1016_j_pbb_2008_02_002 crossref_primary_10_1176_appi_ajp_162_8_1403 crossref_primary_10_1007_s00213_012_2837_3 crossref_primary_10_1038_mp_2013_51 crossref_primary_10_1111_j_1527_3458_2006_00149_x crossref_primary_10_1016_j_ejphar_2003_11_068 crossref_primary_10_1016_j_neuint_2005_08_010 crossref_primary_10_1016_S0014_2999_03_01904_6 crossref_primary_10_1016_j_bcp_2007_06_039 crossref_primary_10_1007_s00213_008_1144_5 crossref_primary_10_1002_syn_10242 crossref_primary_10_1016_j_biopsych_2017_11_021 crossref_primary_10_1016_j_ejphar_2009_01_049 crossref_primary_10_1038_nrn1298 crossref_primary_10_1007_s00213_007_0753_8 crossref_primary_10_1007_s00213_005_2175_9 crossref_primary_10_1080_13556210500223272 crossref_primary_10_1371_journal_pone_0041824 crossref_primary_10_1124_pharmrev_121_000540 crossref_primary_10_3181_0712_MR_355 crossref_primary_10_3389_fphar_2014_00158 |
Cites_doi | 10.1523/JNEUROSCI.22-13-05669.2002 10.1016/0091-3057(89)90483-8 10.1093/alcalc/37.5.495 10.1523/JNEUROSCI.22-07-02977.2002 10.1126/science.7569895 10.1016/0304-3940(93)90227-C 10.1038/nn0901-873 10.1016/S0031-6997(24)01492-3 10.1016/S0014-2999(00)00697-X 10.1016/0091-3057(93)90493-D 10.1016/S0006-8993(97)01141-4 10.1016/0006-8993(90)90431-A 10.1016/S0306-4530(97)00027-9 10.1002/(SICI)1098-2396(199901)31:1<76::AID-SYN10>3.0.CO;2-Y 10.1016/S0924-977X(97)00087-4 10.1016/S0022-3565(24)39029-9 10.1046/j.1471-4159.2000.0750889.x 10.1080/14622200050011277 10.1111/j.1749-6632.2001.tb03560.x 10.1146/annurev.pharmtox.37.1.205 10.1046/j.0953-816x.2001.01584.x 10.1016/S0896-6273(02)00625-6 10.1016/0006-8993(93)91461-Z 10.1016/0091-3057(94)00221-4 10.1016/S0165-6147(00)01694-1 10.1002/1098-2396(20001215)38:4<375::AID-SYN2>3.0.CO;2-Y 10.1016/0014-2999(95)00630-3 10.1016/S0924-977X(98)00025-X 10.1523/JNEUROSCI.22-09-03338.2002 10.1016/S0028-3908(01)00083-1 10.1016/S0091-3057(01)00548-2 10.1046/j.1471-4159.1999.0720157.x 10.1016/S0022-3565(24)29296-X 10.1016/S0014-2999(99)00431-8 10.1037/0735-7044.112.6.1423 10.1016/S0028-3908(01)00036-3 10.1016/0091-3057(92)90382-P 10.1016/0924-977X(95)00066-X 10.1016/S0028-3908(02)00332-5 10.1016/S0149-7634(98)00055-4 10.1016/S0028-3908(99)00242-7 10.1007/BF02244174 10.1007/s00213-001-0953-6 10.1007/s002130000586 10.1523/JNEUROSCI.22-06-02135.2002 10.1006/mcne.2001.0992 10.1038/sj.bjp.0703923 10.1007/s002130050837 10.1016/S0166-4328(00)00311-9 10.1016/S0028-3908(99)00082-9 10.1016/S0014-2999(96)00961-2 10.1007/s00213-001-0965-2 10.1002/syn.10073 10.1002/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0.CO;2-D 10.1016/S0149-7634(98)00045-1 10.1097/00001756-199511270-00011 10.1080/14622200110073380 |
ContentType | Journal Article |
Copyright | 2003 INIST-CNRS Copyright Springer-Verlag 2003 |
Copyright_xml | – notice: 2003 INIST-CNRS – notice: Copyright Springer-Verlag 2003 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 88G 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
DOI | 10.1007/s00213-003-1432-z |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Chemoreception Abstracts Proquest Nursing & Allied Health Source Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Technology Research Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Proquest Medical Database Psychology Database (Proquest) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Animal Behavior Abstracts ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic ProQuest One Psychology Animal Behavior Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-2072 |
EndPage | 264 |
ExternalDocumentID | 723535151 12682710 14862478 10_1007_s00213_003_1432_z |
Genre | Research Support, U.S. Gov't, P.H.S Comparative Study Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NIDA NIH HHS grantid: DA11946 – fundername: NIDA NIH HHS grantid: R56 DA011946 |
GroupedDBID | .55 3SX 40D 40E 95. 95~ AAYXX ABMNI AGWIL ALMA_UNASSIGNED_HOLDINGS CITATION KOW N2Q R9- RHV SBY SOJ X7M ~EX IQODW -4W -BR CGR CUY CVF ECM EIF NPM 3V. 7QG 7QR 7RV 7TK 7X7 7XB 88E 8AO 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GNUQQ K9. M1P M2M NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
ID | FETCH-LOGICAL-c385t-78424940e2a6192d207fdf637331c13edd939c697979ccaced5bdccf8f9764883 |
IEDL.DBID | 7X7 |
ISSN | 0033-3158 |
IngestDate | Fri Jul 11 00:21:20 EDT 2025 Fri Jul 11 04:40:42 EDT 2025 Thu Aug 14 11:38:17 EDT 2025 Sat Sep 28 07:46:52 EDT 2024 Wed Apr 02 07:27:47 EDT 2025 Thu Jul 03 08:24:01 EDT 2025 Thu Apr 24 23:02:20 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Intraperitoneal administration Intravenous administration Rat Self administration Dose activity relation Learning Alkaloid Acquisition process Dependence Reinforcement Antagonist Mechanism of action Self-administration mglu5 glutamate receptor Poison withdrawal Rodentia Rats Instrumental conditioning MPEP Biological activity Vertebrata Mammalia Mouse Animal Mice mGluR5 Nicotine |
Language | English |
License | http://www.springer.com/tdm CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c385t-78424940e2a6192d207fdf637331c13edd939c697979ccaced5bdccf8f9764883 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 |
PMID | 12682710 |
PQID | 218957416 |
PQPubID | 47309 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_73276810 proquest_miscellaneous_18752103 proquest_journals_218957416 pubmed_primary_12682710 pascalfrancis_primary_14862478 crossref_citationtrail_10_1007_s00213_003_1432_z crossref_primary_10_1007_s00213_003_1432_z |
PublicationCentury | 2000 |
PublicationDate | 2003-05-01 |
PublicationDateYYYYMMDD | 2003-05-01 |
PublicationDate_xml | – month: 05 year: 2003 text: 2003-05-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin – name: Germany – name: Heidelberg |
PublicationTitle | Psychopharmacologia |
PublicationTitleAlternate | Psychopharmacology (Berl) |
PublicationYear | 2003 |
Publisher | Springer Springer Nature B.V |
Publisher_xml | – name: Springer – name: Springer Nature B.V |
References | Battaglia (1432_CR1) 2001; 17 Spooren (1432_CR48) 2000; 406 File (1432_CR15) 1998; 112 Goeders (1432_CR18) 1997; 22 Goeders (1432_CR19) 1989; 33 Stolerman (1432_CR51) 1999; 141 Dewey (1432_CR13) 1999; 31 Semenova (1432_CR44) 1995; 50 Shaham (1432_CR46) 1992; 41 Sarnyai (1432_CR40) 2001; 53 Corrigall (1432_CR9) 1991; 104 David (1432_CR12) 2001; 13 Ramsay (1432_CR38) 1993; 608 Ossowska (1432_CR34) 2001; 41 Kuzmin (1432_CR25) 1996; 6 Gasparini (1432_CR16) 1999; 38 Vezina (1432_CR55) 1999; 23 Conn (1432_CR8) 1997; 37 Semenova (1432_CR45) 1999; 378 Kuzmin (1432_CR28) 1999; 9 Corrigall (1432_CR10) 2002; 160 Chiamulera (1432_CR7) 2001; 4 Caine (1432_CR4) 2002; 22 1432_CR22 Martellotta (1432_CR31) 1998; 8 Watkins (1432_CR56) 2000; 2 Miner (1432_CR33) 1995; 6 Spooren (1432_CR50) 2001; 22 Reid (1432_CR39) 2000; 35 Schulz (1432_CR43) 2001; 41 Picciotto (1432_CR37) 2002; 22 Breysse (1432_CR3) 2002; 22 Spooren (1432_CR49) 2000; 295 Schoepp (1432_CR42) 2001; 299 Zhang (1432_CR57) 2001; 937 Paterson (1432_CR35) 2002; 44 Piazza (1432_CR36) 1990; 514 Chapman (1432_CR6) 2000; 39 Holscher (1432_CR23) 2001; 23 Ghasemzadeh (1432_CR17) 1999; 72 Kuzmin (1432_CR26) 1996; 295 Schilstrom (1432_CR41) 2000; 38 Cossu (1432_CR11) 2001; 118 Irvine (1432_CR24) 2001; 153 Tatarczynska (1432_CR54) 2001; 132 Shigemoto (1432_CR47) 1993; 163 Harrison (1432_CR21) 2002; 160 Szyndler (1432_CR52) 2001; 69 Battaglia (1432_CR2) 2002; 22 Kuzmin (1432_CR27) 1997; 321 Cartmell (1432_CR5) 2000; 75 Tallaksen-Greene (1432_CR53) 1998; 780 McGehee (1432_CR32) 1995; 269 Markou (1432_CR30) 2001; 3 Goeders (1432_CR20) 1993; 44 Fattore (1432_CR14) 2002; 37 Mansvelder (1432_CR29) 2002; 33 11072438 - Nicotine Tob Res. 2000 Feb;2(1):19-37 7700949 - Pharmacol Biochem Behav. 1995 Jan;50(1):17-21 7569895 - Science. 1995 Sep 22;269(5231):1692-6 9926824 - Behav Neurosci. 1998 Dec;112(6):1423-9 11422457 - Eur J Neurosci. 2001 Jun;13(11):2157-64 11509211 - Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):511-8 11528416 - Nat Neurosci. 2001 Sep;4(9):873-4 11984860 - Synapse. 2002 Jun 15;44(4):252-3 11896153 - J Neurosci. 2002 Mar 15;22(6):2135-41 11414795 - Mol Cell Neurosci. 2001 Jun;17(6):1071-83 10854901 - Neuropharmacology. 2000 Jul 10;39(9):1567-74 8295733 - Neurosci Lett. 1993 Nov 26;163(1):53-7 12217945 - Alcohol Alcohol. 2002 Sep-Oct;37(5):495-8 8866940 - Eur Neuropsychopharmacol. 1996 Mar;6(1):63-8 11264235 - Br J Pharmacol. 2001 Apr;132(7):1423-30 10611638 - Synapse. 2000 Feb;35(2):129-36 11875638 - Psychopharmacology (Berl). 2002 Mar;160(2):198-205 11978809 - J Neurosci. 2002 May 1;22(9):3338-41 8495356 - Brain Res. 1993 Apr 16;608(2):216-22 10530811 - Neuropharmacology. 1999 Oct;38(10 ):1493-503 9989427 - Neurosci Biobehav Rev. 1999;23(3):399-410 10073895 - Neurosci Biobehav Rev. 1999 Mar;23(4):577-89 11082464 - J Pharmacol Exp Ther. 2000 Dec;295(3):1267-75 11445180 - Neuropharmacology. 2001 Jul;41(1):1-7 11163634 - Behav Brain Res. 2001 Jan 8;118(1):61-5 11923462 - J Neurosci. 2002 Apr 1;22(7):2977-88 2559416 - Pharmacol Biochem Behav. 1989 Aug;33(4):859-66 9928919 - Eur Neuropsychopharmacol. 1998 Dec;8(4):293-6 11040347 - Eur J Pharmacol. 2000 Oct 20;406(3):403-10 11561058 - J Pharmacol Exp Ther. 2001 Oct;299(1):12-20 11543761 - Neuropharmacology. 2001 Sep;41(4):413-20 11044884 - Synapse. 2000 Dec 15;38(4):375-83 9085036 - Eur J Pharmacol. 1997 Mar 5;321(3):265-71 10025686 - Synapse. 1999 Jan;31(1):76-86 11271403 - Psychopharmacology (Berl). 2001 Jan;153(3):315-20 1584842 - Pharmacol Biochem Behav. 1992 Mar;41(3):615-9 9131252 - Annu Rev Pharmacol Toxicol. 1997;37:205-37 10936169 - J Neurochem. 2000 Sep;75(3):889-907 8925870 - Eur J Pharmacol. 1996 Jan 4;295(1):19-25 12527469 - Neuropharmacology. 2002 Dec;43(8):1199-209 8446681 - Pharmacol Biochem Behav. 1993 Feb;44(2):471-4 11458542 - Ann N Y Acad Sci. 2001 Jun;937:93-120 9226728 - Psychoneuroendocrinology. 1997 May;22(4):237-59 9507137 - Brain Res. 1998 Jan 12;780(2):210-7 11694204 - Nicotine Tob Res. 2001 Nov;3(4):361-73 9886066 - J Neurochem. 1999 Jan;72(1):157-65 8747144 - Neuroreport. 1995 Nov 27;6(17):2314-6 10478558 - Eur J Pharmacol. 1999 Jul 28;378(1):1-8 1876661 - Psychopharmacology (Berl). 1991;104(2):171-6 11356984 - Pharmacol Rev. 2001 Jun;53(2):209-43 12097518 - J Neurosci. 2002 Jul 1;22(13):5669-78 11906697 - Neuron. 2002 Mar 14;33(6):905-19 10208288 - Eur Neuropsychopharmacol. 1999 Mar;9(3):197-203 11431019 - Trends Pharmacol Sci. 2001 Jul;22(7):331-7 2357527 - Brain Res. 1990 Apr 23;514(1):22-6 10027511 - Psychopharmacology (Berl). 1999 Jan;141(3):297-306 11862374 - Psychopharmacology (Berl). 2002 Feb;160(1):56-66 |
References_xml | – volume: 22 start-page: 5669 year: 2002 ident: 1432_CR3 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-13-05669.2002 – volume: 33 start-page: 859 year: 1989 ident: 1432_CR19 publication-title: Pharmacol Biochem Behav doi: 10.1016/0091-3057(89)90483-8 – volume: 37 start-page: 495 year: 2002 ident: 1432_CR14 publication-title: Alcohol Alcohol doi: 10.1093/alcalc/37.5.495 – volume: 22 start-page: 2977 year: 2002 ident: 1432_CR4 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-07-02977.2002 – volume: 269 start-page: 1692 year: 1995 ident: 1432_CR32 publication-title: Science doi: 10.1126/science.7569895 – volume: 163 start-page: 53 year: 1993 ident: 1432_CR47 publication-title: Neurosci Lett doi: 10.1016/0304-3940(93)90227-C – volume: 4 start-page: 873 year: 2001 ident: 1432_CR7 publication-title: Nature Neurosci doi: 10.1038/nn0901-873 – volume: 53 start-page: 209 year: 2001 ident: 1432_CR40 publication-title: Pharmacol Rev doi: 10.1016/S0031-6997(24)01492-3 – volume: 406 start-page: 403 year: 2000 ident: 1432_CR48 publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(00)00697-X – volume: 44 start-page: 471 year: 1993 ident: 1432_CR20 publication-title: Pharmacol Biochem Behav doi: 10.1016/0091-3057(93)90493-D – volume: 780 start-page: 210 year: 1998 ident: 1432_CR53 publication-title: Brain Res doi: 10.1016/S0006-8993(97)01141-4 – volume: 514 start-page: 22 year: 1990 ident: 1432_CR36 publication-title: Brain Res doi: 10.1016/0006-8993(90)90431-A – volume: 22 start-page: 237 year: 1997 ident: 1432_CR18 publication-title: Psychoneuroendocrinology doi: 10.1016/S0306-4530(97)00027-9 – volume: 31 start-page: 76 year: 1999 ident: 1432_CR13 publication-title: Synapse doi: 10.1002/(SICI)1098-2396(199901)31:1<76::AID-SYN10>3.0.CO;2-Y – volume: 8 start-page: 293 year: 1998 ident: 1432_CR31 publication-title: Eur Neuropsychopharmacol doi: 10.1016/S0924-977X(97)00087-4 – volume: 295 start-page: 1267 year: 2000 ident: 1432_CR49 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)39029-9 – volume: 75 start-page: 889 year: 2000 ident: 1432_CR5 publication-title: J Neurochem doi: 10.1046/j.1471-4159.2000.0750889.x – volume: 2 start-page: 19 year: 2000 ident: 1432_CR56 publication-title: Nicotine Tob Res doi: 10.1080/14622200050011277 – volume: 937 start-page: 93 year: 2001 ident: 1432_CR57 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2001.tb03560.x – volume: 37 start-page: 205 year: 1997 ident: 1432_CR8 publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pharmtox.37.1.205 – volume: 13 start-page: 2157 year: 2001 ident: 1432_CR12 publication-title: Eur J Neurosci doi: 10.1046/j.0953-816x.2001.01584.x – volume: 33 start-page: 905 year: 2002 ident: 1432_CR29 publication-title: Neuron doi: 10.1016/S0896-6273(02)00625-6 – volume: 608 start-page: 216 year: 1993 ident: 1432_CR38 publication-title: Brain Res doi: 10.1016/0006-8993(93)91461-Z – volume: 50 start-page: 17 year: 1995 ident: 1432_CR44 publication-title: Pharmacol Biochem Behav doi: 10.1016/0091-3057(94)00221-4 – volume: 22 start-page: 331 year: 2001 ident: 1432_CR50 publication-title: Trends Pharmacol Sci doi: 10.1016/S0165-6147(00)01694-1 – volume: 38 start-page: 375 year: 2000 ident: 1432_CR41 publication-title: Synapse doi: 10.1002/1098-2396(20001215)38:4<375::AID-SYN2>3.0.CO;2-Y – volume: 295 start-page: 19 year: 1996 ident: 1432_CR26 publication-title: Eur J Pharmacol doi: 10.1016/0014-2999(95)00630-3 – volume: 9 start-page: 197 year: 1999 ident: 1432_CR28 publication-title: Eur Neuropsychopharmacol doi: 10.1016/S0924-977X(98)00025-X – volume: 22 start-page: 3338 year: 2002 ident: 1432_CR37 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-09-03338.2002 – volume: 41 start-page: 413 year: 2001 ident: 1432_CR34 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(01)00083-1 – volume: 69 start-page: 511 year: 2001 ident: 1432_CR52 publication-title: Pharmacol Biochem Behav doi: 10.1016/S0091-3057(01)00548-2 – volume: 72 start-page: 157 year: 1999 ident: 1432_CR17 publication-title: J Neurochem doi: 10.1046/j.1471-4159.1999.0720157.x – volume: 299 start-page: 12 year: 2001 ident: 1432_CR42 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)29296-X – volume: 378 start-page: 1 year: 1999 ident: 1432_CR45 publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(99)00431-8 – volume: 112 start-page: 1423 year: 1998 ident: 1432_CR15 publication-title: Behav Neurosci doi: 10.1037/0735-7044.112.6.1423 – volume: 41 start-page: 1 year: 2001 ident: 1432_CR43 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(01)00036-3 – volume: 41 start-page: 615 year: 1992 ident: 1432_CR46 publication-title: Pharmacol Biochem Behav doi: 10.1016/0091-3057(92)90382-P – volume: 6 start-page: 63 year: 1996 ident: 1432_CR25 publication-title: Eur Neuropsychopharmacol doi: 10.1016/0924-977X(95)00066-X – ident: 1432_CR22 doi: 10.1016/S0028-3908(02)00332-5 – volume: 23 start-page: 577 year: 1999 ident: 1432_CR55 publication-title: Neurosci Biobehav Rev doi: 10.1016/S0149-7634(98)00055-4 – volume: 39 start-page: 1567 year: 2000 ident: 1432_CR6 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(99)00242-7 – volume: 104 start-page: 171 year: 1991 ident: 1432_CR9 publication-title: Psychopharmacology doi: 10.1007/BF02244174 – volume: 160 start-page: 56 year: 2002 ident: 1432_CR21 publication-title: Psychopharmacology doi: 10.1007/s00213-001-0953-6 – volume: 153 start-page: 315 year: 2001 ident: 1432_CR24 publication-title: Psychopharmacology doi: 10.1007/s002130000586 – volume: 22 start-page: 2135 year: 2002 ident: 1432_CR2 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.22-06-02135.2002 – volume: 17 start-page: 1071 year: 2001 ident: 1432_CR1 publication-title: Mol Cell Neurosci doi: 10.1006/mcne.2001.0992 – volume: 132 start-page: 1423 year: 2001 ident: 1432_CR54 publication-title: Br J Pharmacol doi: 10.1038/sj.bjp.0703923 – volume: 141 start-page: 297 year: 1999 ident: 1432_CR51 publication-title: Psychopharmacology doi: 10.1007/s002130050837 – volume: 118 start-page: 61 year: 2001 ident: 1432_CR11 publication-title: Behav Brain Res doi: 10.1016/S0166-4328(00)00311-9 – volume: 38 start-page: 1493 year: 1999 ident: 1432_CR16 publication-title: Neuropharmacology doi: 10.1016/S0028-3908(99)00082-9 – volume: 321 start-page: 265 year: 1997 ident: 1432_CR27 publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(96)00961-2 – volume: 160 start-page: 198 year: 2002 ident: 1432_CR10 publication-title: Psychopharmacology doi: 10.1007/s00213-001-0965-2 – volume: 44 start-page: 252 year: 2002 ident: 1432_CR35 publication-title: Synapse doi: 10.1002/syn.10073 – volume: 35 start-page: 129 year: 2000 ident: 1432_CR39 publication-title: Synapse doi: 10.1002/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0.CO;2-D – volume: 23 start-page: 399 year: 2001 ident: 1432_CR23 publication-title: Neurosci Biobehav Rev doi: 10.1016/S0149-7634(98)00045-1 – volume: 6 start-page: 2314 year: 1995 ident: 1432_CR33 publication-title: Neuroreport doi: 10.1097/00001756-199511270-00011 – volume: 3 start-page: 361 year: 2001 ident: 1432_CR30 publication-title: Nicotine Tob Res doi: 10.1080/14622200110073380 – reference: 8495356 - Brain Res. 1993 Apr 16;608(2):216-22 – reference: 8866940 - Eur Neuropsychopharmacol. 1996 Mar;6(1):63-8 – reference: 11072438 - Nicotine Tob Res. 2000 Feb;2(1):19-37 – reference: 11422457 - Eur J Neurosci. 2001 Jun;13(11):2157-64 – reference: 11528416 - Nat Neurosci. 2001 Sep;4(9):873-4 – reference: 11082464 - J Pharmacol Exp Ther. 2000 Dec;295(3):1267-75 – reference: 11163634 - Behav Brain Res. 2001 Jan 8;118(1):61-5 – reference: 10025686 - Synapse. 1999 Jan;31(1):76-86 – reference: 11431019 - Trends Pharmacol Sci. 2001 Jul;22(7):331-7 – reference: 9928919 - Eur Neuropsychopharmacol. 1998 Dec;8(4):293-6 – reference: 9886066 - J Neurochem. 1999 Jan;72(1):157-65 – reference: 11862374 - Psychopharmacology (Berl). 2002 Feb;160(1):56-66 – reference: 10478558 - Eur J Pharmacol. 1999 Jul 28;378(1):1-8 – reference: 8295733 - Neurosci Lett. 1993 Nov 26;163(1):53-7 – reference: 7700949 - Pharmacol Biochem Behav. 1995 Jan;50(1):17-21 – reference: 11271403 - Psychopharmacology (Berl). 2001 Jan;153(3):315-20 – reference: 11978809 - J Neurosci. 2002 May 1;22(9):3338-41 – reference: 9085036 - Eur J Pharmacol. 1997 Mar 5;321(3):265-71 – reference: 11561058 - J Pharmacol Exp Ther. 2001 Oct;299(1):12-20 – reference: 12217945 - Alcohol Alcohol. 2002 Sep-Oct;37(5):495-8 – reference: 11044884 - Synapse. 2000 Dec 15;38(4):375-83 – reference: 2559416 - Pharmacol Biochem Behav. 1989 Aug;33(4):859-66 – reference: 1584842 - Pharmacol Biochem Behav. 1992 Mar;41(3):615-9 – reference: 11896153 - J Neurosci. 2002 Mar 15;22(6):2135-41 – reference: 11356984 - Pharmacol Rev. 2001 Jun;53(2):209-43 – reference: 11414795 - Mol Cell Neurosci. 2001 Jun;17(6):1071-83 – reference: 10936169 - J Neurochem. 2000 Sep;75(3):889-907 – reference: 11509211 - Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):511-8 – reference: 10208288 - Eur Neuropsychopharmacol. 1999 Mar;9(3):197-203 – reference: 8925870 - Eur J Pharmacol. 1996 Jan 4;295(1):19-25 – reference: 9226728 - Psychoneuroendocrinology. 1997 May;22(4):237-59 – reference: 10073895 - Neurosci Biobehav Rev. 1999 Mar;23(4):577-89 – reference: 2357527 - Brain Res. 1990 Apr 23;514(1):22-6 – reference: 7569895 - Science. 1995 Sep 22;269(5231):1692-6 – reference: 10854901 - Neuropharmacology. 2000 Jul 10;39(9):1567-74 – reference: 10027511 - Psychopharmacology (Berl). 1999 Jan;141(3):297-306 – reference: 1876661 - Psychopharmacology (Berl). 1991;104(2):171-6 – reference: 12527469 - Neuropharmacology. 2002 Dec;43(8):1199-209 – reference: 11923462 - J Neurosci. 2002 Apr 1;22(7):2977-88 – reference: 11458542 - Ann N Y Acad Sci. 2001 Jun;937:93-120 – reference: 11875638 - Psychopharmacology (Berl). 2002 Mar;160(2):198-205 – reference: 11984860 - Synapse. 2002 Jun 15;44(4):252-3 – reference: 11445180 - Neuropharmacology. 2001 Jul;41(1):1-7 – reference: 8747144 - Neuroreport. 1995 Nov 27;6(17):2314-6 – reference: 9507137 - Brain Res. 1998 Jan 12;780(2):210-7 – reference: 11264235 - Br J Pharmacol. 2001 Apr;132(7):1423-30 – reference: 8446681 - Pharmacol Biochem Behav. 1993 Feb;44(2):471-4 – reference: 11694204 - Nicotine Tob Res. 2001 Nov;3(4):361-73 – reference: 10611638 - Synapse. 2000 Feb;35(2):129-36 – reference: 11040347 - Eur J Pharmacol. 2000 Oct 20;406(3):403-10 – reference: 9131252 - Annu Rev Pharmacol Toxicol. 1997;37:205-37 – reference: 12097518 - J Neurosci. 2002 Jul 1;22(13):5669-78 – reference: 9926824 - Behav Neurosci. 1998 Dec;112(6):1423-9 – reference: 10530811 - Neuropharmacology. 1999 Oct;38(10 ):1493-503 – reference: 9989427 - Neurosci Biobehav Rev. 1999;23(3):399-410 – reference: 11906697 - Neuron. 2002 Mar 14;33(6):905-19 – reference: 11543761 - Neuropharmacology. 2001 Sep;41(4):413-20 |
SSID | ssj0000484 ssj0068394 |
Score | 2.2025964 |
Snippet | Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic... Rationale. Nicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 257 |
SubjectTerms | Animals Behavior, Animal - drug effects Biological and medical sciences Dose-Response Relationship, Drug Drug Administration Routes - veterinary Drug Administration Schedule - veterinary Drug Interactions Excitatory Amino Acid Antagonists - pharmacology Feeding Behavior - drug effects Male Medical sciences Mice Mice, Inbred DBA Nicotine - administration & dosage Nicotinic Agonists - administration & dosage Pyridines - pharmacology Rats Rats, Wistar Receptor, Metabotropic Glutamate 5 Receptors, Metabotropic Glutamate - antagonists & inhibitors Receptors, Metabotropic Glutamate - physiology Reinforcement Schedule Self Administration - methods Self Administration - veterinary Tobacco, tobacco smoking Toxicology |
Title | The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice |
URI | https://www.ncbi.nlm.nih.gov/pubmed/12682710 https://www.proquest.com/docview/218957416 https://www.proquest.com/docview/18752103 https://www.proquest.com/docview/73276810 |
Volume | 167 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9swED62FsZgjK3bOq9dpofRh1Ex27Is-6k0W7IySDGhhbwZVz9KIXOyOXlo__rdyU5MHlr8YBtJltGdpO-k03cAX8NMu8i6nKvU5Jwo33gVauzuJtRO6FQbRwv6k8v04jr5PZOzzjen6dwqN2OiH6jNQtMa-XecinJJ8OFs-ZdT0CjaXO0iaDyHfc9chuqsZqofiBM6g9m-pAgEWkZmQefJZLbZ4Qw9oWhMMQ7ISwv_lj_szFGvllWDzeXaOBePA1E_IY3fwOsOSbLzVvRv4ZmtD-DFpNsrP4CTomWlvj9lV_0hq-aUnbCi56u-fwdTTGZ_fs3XU8mwnavbBbHpskkxKpjxqLKxhtWoMiv8MGvs3PFqh3OX3dUMnxosbhjFt38P1-PR1Y8L3oVa4FpkcsVVlqAdloQ2rsiiMnGonHGpoIiOOhLWmFzkOs0VXihzbY28MVq7zCGcwTFAfIC9elHbj8ASVZHVK12EyDLOo0prnSOOk1ZKhWA0gHDTuKXueMgpHMa83DIoe3kQa2lJ8igfAvi2LbJsSTieyjzYkVhfIqHDMCoL4GgjwrLrsE25Va8AvmxTsafR9klV28W6KSM07dBAFo_nUCJWxO8WwGGrGX3dcZrFCOY-PVn3Ebz0voLen_IY9lb_1vYzYp7VzcBr9gD2z4c_h2O8D0eXxfQ_CT_-TA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVAIkhKC8TKHdA_SAusL2ev04IMQjJaVNZEWp1Jtx94GQUifgRCj9T_xHZvyIlUN7q3yxZa9X9szOfrOz8w3AGzdW1jM24VGoE06Ubzx3FQ537SorVKi0pQX94SgcnAXfz-X5Fvxrc2FoW2VrEytDrWeK1sjf41SUSIIPH-e_ORWNouBqW0Gj1ooTs_qLHlv54fgrivet7x_1J18GvCkqwJWI5YJHcYAeR-AaPyffQftuZLUNBdUuVJ4wWiciUWES4YFfp4yWF1opG1ucuFHbBb73DmwHlNDag-3P_VE67kx_QFmf9UWI0KPmgBaUwSbjNqbqVhSmPlVVoH1h-H_41cas-GCelyggW1fWuB76VlPg0SN42GBX9qlWtsewZYoduDtsovM7cJDWPNirQzbp0rrKQ3bA0o4he_UExnibXX6bLseSoWTznzPi72XDtJ8yXeHY0mhWoJIu8MWsNFPL8w2WX_arYHhWYnPNLtHYPYWzW5HDM-gVs8K8ABZEOfnZ0nqIZf3Ey5VSCSJHaaSMEP464LY_N1MN8zkV4Jhma87mSh7Ek5qRPLIrB96tm8xr2o-bHt7bkFjXIqD0myh2YLcVYdaYiDJbK7QD--u7OLYpYJMXZrYsMw-dSXTJxfVPRMKPiFHOgee1ZnR9-2HsI3x8eWPf-3BvMBmeZqfHo5NduF_tVKx2c76C3uLP0rxGxLW42Gv0nMGP2x5a_wFJITlk |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB9qhSKIaP2K1XYftA_S0GQ3m00eRMT2bK1XQmnh3tJ0P0S45k5zh1z_M_87Z_Jx4R7at5KXhGQTkpnZ-U125jcA74NEu9C61FexSX2ifPOLQKO5m0A7oWNtHP3QH57GRxfR95EcrcG_rhaG0iq7ObGeqM1E0z_yfXRFqST4sO_arIjsYPB5-tunBlK00Np102g05MQu_mL0Vn06PkBRf-B8cHj-9chvGwz4WiRy5qskwugjCiwvKI4wPFDOuFhQH0MdCmtMKlIdpwo3fFNtjbwyWrvEoRNHzRd43wfwUAkEVWhKaqR6JxBR_WdzECMIadigBdWyyaRbXQ1qMlNO_RUoQwy_lH-z4h8fT4sKReWaHhu3g-DaGQ6ewpMWxbIvjdo9gzVbbsLGsF2n34TdrGHEXuyx877Aq9pjuyzrubIXz-EMT7Prb-P5mWQo4-LnhJh82TA7zJipEW1lDStRXWd4Y1bZsfOLFb5f9qtkuFfhcMOucdp7ARf3IoWXsF5OSvsaWKQKirilCxHV8jQstNYpYkhppVQIhD0Iuo-b65YDnVpxjPMle3MtD2JMzUke-Y0HH5dDpg0ByF0Xb69IrB8RUSGOSjzY6kSYt5NFlS9V24Od5Vm0clq6KUo7mVd5iGElBufi9iuU4Iq45Tx41WhG_2weJxyB5Js7n70DG2hQ-Y_j05MteFSnLNZpnW9hffZnbt8h9JpdbddKzuDyvq3qP4y9PCs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+mGluR5+antagonist+MPEP+decreased+nicotine+self-administration+in+rats+and+mice&rft.jtitle=Psychopharmacology&rft.au=Paterson%2C+Neil+E.&rft.au=Semenova%2C+Svetlana&rft.au=Gasparini%2C+Fabrizio&rft.au=Markou%2C+Athina&rft.date=2003-05-01&rft.issn=0033-3158&rft.volume=167&rft.issue=3&rft.spage=257&rft.epage=264&rft_id=info:doi/10.1007%2Fs00213-003-1432-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00213_003_1432_z |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon |